At a press conference held in Paris on February 20, 2020, Olivier Laureau, President of Servier, Dominique Brissy, Executive Vice President, Finance and Information Systems, and Claude Bertrand, Executive Vice President R&D, presented the Group’s R&D pipeline and financial results for fiscal year 2018-2019.
The Group revenue in the 2018/19 financial year was 4.615 billion euros, an increase of 10.5%.
“The results of the 2018/19 financial year exceeded our objectives”, commented Dominique Brissy. “This growth was driven by the momentum of the brand-name activities, with good increases in sales, particularly in China, Russia, and Brazil, but also in the area of oncology, in the United States in particular. The generic activities, with an increase of 7.5%, also contributed to the growth.”
Claude Bertrand presented the Group’s R&D pipeline: ″In 2018/19, we intensified the development of our R&D portfolio with the acceleration of key programs, in particular in oncology, and the signing of new strategic research partnership. The pursuit of our open innovation strategy and the acceleration of the transformation of our R&D remain major objectives in order to reinforce our portfolio of drug candidates and ensure added value for patients. The future Servier Paris-Saclay Research Institute, due to open in 2022, perfectly illustrates the innovation dynamic of the Group and will embody its new way of imagining R&D.″
The Group is energetically reinforcing its pipeline as a result of sustained capital investments, investing close to a quarter of its revenue (excluding generic activities) each year in R&D. Today the Group has a promising pipeline of 30 drug candidates and 32 research projects.
Claude Bertrand also recalled the priority nature of oncology research: during the 2018/19 financial year, oncology represented 36% of the Group’s R&D budget, with the objective of reaching 50%.